Histone PTMs as Biomarkers: Opportunities and Limitations for Translational Research

Histone posttranslational modifications (PTMs) are instrumental in regulating gene expression and are strongly linked to various diseases. Notably, their potential as biomarkers is especially significant in cancer and neurodegeneration.

This review explores the opportunities and challenges associated with utilizing histone PTMs as biomarkers. We focus specifically on their application within translational research contexts.

The core value of histone PTMs as a biomarker

Histone Modification (H2BK12cr) as a Translational Research Core for Colorectal Cancer Biomarkers

1. Core Findings and Diagnostic Value

H2BK12 crotonylation (H2BK12cr) levels were significantly elevated in PBMCs from CRC patients compared to healthy controls. This marker demonstrated strong clinical relevance, showing positive correlations with distant metastasis (*p* = 0.0478) and advanced TNM stage (*p* = 0.0201).

• Diagnostically, H2BK12cr outperformed conventional markers:
  • AUC of 0.8488 exceeded that of CEA
  • Sensitivity (70%) approached the FDA-approved SEPT9 assay (68%)
  • Specificity (92.5%) surpassed the 90% CMS reimbursement threshold

2. Translational Advantages

• Technical simplicity: The assay requires only peripheral blood PBMC isolation followed by Western blotting, eliminating the need for complex omics platforms (e.g., PCR, mass spectrometry). This low-cost approach enhances feasibility in resource-limited settings.
• Minimally invasive screening: Blood-based testing achieves high patient compliance, addressing the critical limitation of low colonoscopy screening rates (which declined to 5-15% during pandemics).

3. Clinical Translation Limitations

• Current constraints include:
  • Unvalidated sensitivity for adenomas/early-stage CRC due to cohort enrichment with advanced cases
  • Undefined functional role of H2BK12cr in CRC pathogenesis
  • Future work must elucidate its regulatory gene networks and signaling pathways.

4. Application Prospects and Optimization

• Hierarchical diagnostics:
  • Combine H2BK12cr with SEPT9 methylation to boost early-stage sensitivity (>80% target)
  • Monitor dynamic H2BK12cr changes during therapy to predict metastasis/treatment resistance (e.g., post-chemotherapy progression)
• Technology evolution:
  • Develop POCT devices for bedside H2BK12cr quantification (glucose-meter paradigm)
  • Integrate with liquid biopsy (e.g., ctDNA methylation) to build multimodal screening panels (Hou, JY et al., 2023)

Association of H2BK12cr level with TNM stages of CRC (Hou JY et al., 2023)

Translational Studies of Histone Citrullination (H3Cit) as a Cancer Biomarker

1. Core Advantages and Clinical Value

• Diagnostic and prognostic utility:
  • Serum H3Cit concentrations are 3-fold higher in advanced cancer patients versus healthy individuals
  • Levels >29.8 ng/mL (75th percentile) significantly correlate with short-term mortality risk
  • Elevated H3Cit distinguishes metastatic from localized tumors, consistent with PAD-mediated metastasis mechanisms
• Inflammatory association: Strong positive correlation with neutrophil markers (IL-6, IL-8, elastase) reflects systemic inflammatory burden
• Therapeutic guidance value:
  • Thromboembolism prediction: H3Cit independently predicts VTE during cancer therapy → guides anticoagulant prophylaxis
  • Drug resistance monitoring: PAD2-mediated H3Cit26↑ promotes IL-6 expression → drives chemoresistance (myeloma model)
  • Therapeutic target: PAD inhibitors reduce H3Cit → enhance antitumor activity (CRC model)
  • Combination strategy: PAD + HDAC inhibitors synergistically suppress cancer growth

2. Translational Bottlenecks and Limitations

• Detection challenges:
  • Citrullination quantification difficulties due to lacking high-sensitivity antibodies
  • Current indirect assessments (ELISA/PCR) depend on PAD enzyme levels
  • Standardization deficits: H3Cit measurements vary significantly with sample processing/storage conditions
• Biological complexity:
  • Cancer heterogeneity: PAD2 downregulation in colorectal cancer limits H3Cit's pan-cancer applicability
  • Dual functionality: Pro-metastatic effects versus immune activation roles require microenvironmental context differentiation
• Clinical validation gaps:
  • Predominantly retrospective data (e.g., 29.8 ng/mL threshold needs multicenter validation)
  • No systematic studies correlating therapy-induced H3Cit changes with treatment outcomes

3. Breakthrough Directions and Solutions

• Technological innovation:
  • High-sensitivity nanobodies targeting H3Cit epitopes → improved serum detection
  • LC-MS/MS development → direct citrullinated peptide quantification
  • AI-powered tools (e.g., CKSAAP-CitrSite) → citrullination site prediction for antibody design
• Clinical application strategies:
  • Layered implementation:
    • Prognostic marker in high-PAD4 cancers (lung cancer, lymphoma)
    • PAD2-H3Cit26 axis targeting reverses drug resistance (prostate cancer)
  • Multimodal integration: H3Cit + ctDNA methylation + inflammatory cytokines → composite prognostic models
• Mechanistic exploration:
  • Elucidate H3Cit's causal role in NETosis-mediated cancer metastasis → develop NETosis inhibitors
  • Investigate crosstalk between citrullination, acetylation, and methylation → design combined epidrug therapies (Zhu, D et al., 2021)

Mechanism by which NETs promote tumors (Zhu D et al., 2021)

Histone Modifications as a Research Core for DIPG Biomarkers

1. Core Findings and Biomarker Value

• H3K27M mutation quantification:
  • Mutant peptides constituted 29.2% of total H3K27 peptides in DIPG cell lines
  • Represented 26.4% in patient tissues, enabling first-time mutation load assessment
  • Clinical parallel: Quantitative EGFR mutation analysis predicts lung cancer targeted therapy efficacy → potential applicability for DIPG epigenetic therapies
• Distinct epigenetic vulnerabilities:
  • H3K36me2↑: Most enriched co-occurring modification on mutant peptides → druggable via NSD2 inhibitors (preclinical)
  • H4K16ac↑: Highest-acetylation residue → targetable with MOF inhibitors (DCS compounds)
  • H3K9me3↑: Significantly elevated post-radiotherapy → synergistic radiosensitization with G9a inhibitors (e.g., BIX-01294)
• Mechanistic insights:
  • H3K36me2 elevation correlates with PRC2 loss → drives H3K27me3 deficiency (DIPG's hallmark epigenetic defect)
  • H3K9me3 upregulation promotes DNA double-strand break repair → mediates radiotherapy resistance

2. Therapeutic Implications

• Radioresistance reversal: Radiotherapy-induced H3K9me3↑ enhances DNA repair → combination with G9a inhibitors overcomes resistance
• Targeted approaches:
  • JQ1 (BET inhibitor): Suppresses oncogene transcription while activating tumor suppressor methylation
  • Triple epigenetic inhibition: Concurrent targeting of H3K36me2 (NSD2i), H4K16ac (MOFi), and H3K9me3 (G9ai)

3. Clinical Translation Bottlenecks

• Sample limitations: Reliance on post-mortem tissues (potential treatment-induced alterations)
• Technical barriers: Mass spectrometry requires ≥100 mg tissue → impractical for small biopsy specimens
• Validation gap: Mutation load correlation with therapeutic response remains clinically unverified

4. Translational Strategies

• Diagnostic refinement:
  • H3K27M quantification → identifies candidates for epigenetic targeted therapies
  • Triple-marker panel (H3K36me2 + H4K16ac + H3K9me3) → enables molecular subtyping
• Therapeutic innovation:
  • Radiotherapy + G9a inhibitors → overcomes radioresistance
  • Sequential JQ1 administration → enhances efficacy of radiotherapy/DNA-damaging agents
• Non-invasive monitoring: Cerebrospinal fluid nucleosome PTM profiling → less invasive alternative to tissue biopsy (An, S et al., 2020)

Predominant histone modification states in DIPG tumor tissue (An S et al., 2020)

More Disease-Associated Histone Modification Biomarkers

1. Diagnostic Value in Specific Diseases

Elevated H3K27me3: Detects solid tumors (e.g., Breast cancer) in tissue biopsies/ctDNA earlier than imaging, achieving >90% sensitivity (Fontes-Sousa, M et al., 2020).

Reduced H3K4me3: H3K4me3-associated molecular patterns can serve as powerful biomarkers of the state of the tumor immune microenvironment (TME) , and may be useful in the diagnosis and treatment of cancer, the H3K4me3-RS system is also able to effectively predict patient response to immune checkpoint blockade (ICB) therapy, including efficacy and drug resistance (Fan, T et al., 2025).

Diminished H3K9ac: Epigenetic markers (low H3K9ac) are directly associated with functional defects in chondrogenesis and susceptibility to osteoarthritis in WJ-MSCs. Detection of TGF βri H3K9ac status in WJ-MSCs allows assessment of the chondrogenic potential of these cells and future osteoarthritis risk. Since umbilical cord tissue is readily accessible at birth, H3K9AC levels of tgfβri in human umbilical cord tissue, such as Wharton's jelly itself or the associated cells contained therein, are higher than those in human umbilical cord tissue, it has been specifically proposed as a potential, detectable“Early warning biomarker” (Qi, Y et al., 2021).

2. Therapy-Guiding Clinical Benefits

Treatment selection in AML: Stratifying patients by H3K4me3 levels (high vs. low) optimizes DNMT inhibitor use or EZH2i combination therapy, increasing complete response rates by 35% (van Dijk, A.D et al., 2021).

Radiotherapy targeting: Spatial mapping of H3K27me3 heterogeneity directs precise radiation field delineation, avoiding overexposure and reducing radiation-induced brain injury by 60% (Fontes-Sousa, M et al., 2020).

Technical Limitations and Challenges in Histone PTM Analysis

1. Detection Technology Bottlenecks

Comparison of major methodologies

• ChIP-seq:
  • Strength: Gold standard for genome-wide modification mapping
  • Limitation: Requires >1 million cells; incompatible with liquid biopsies
• Mass Cytometry (CyTOF):
  • Strength: Single-cell resolution for precise histone PTM quantification
  • Limitation: Low throughput (<50 samples per run)
• Immunohistochemistry (IHC):
  • Strength: Clinically accessible for tissue-section analysis
  • Limitation: Semiquantitative output; cannot discriminate methylation states (e.g., di- vs. trimethylation)

2. Biological Complexity Challenges

• Dynamic volatility: Histone PTMs exhibit rapid functional fluctuations. For example, inflammatory stimuli can induce 300% H3K27ac level changes within one hour. Such high-amplitude dynamics necessitate longitudinal monitoring, as single-timepoint assessments fail to capture functional significance.
• Tissue specificity:
  PTM patterns vary across cell types. The BDNF gene demonstrates opposing H3K4me3 regulation:
  
  • Neurons: Typically activates expression
  • Glial cells: Often represses activity
  • This heterogeneity demands cell-type-specific isolation before analysis to prevent confounding results.
• Modification crosstalk:
  Histone PTMs function cooperatively within regulatory networks. For instance:
  
  • H3K9me3 frequently collaborates with DNA methylation to silence genes
  • Individual marks (e.g., H3K9me3 alone) inadequately predict transcriptional outcomes
  • Consequently, comprehensive mapping of combinatorial PTM patterns is essential for accurate functional interpretation.

Breakthrough Pathways and Innovation Directions

1. Advanced Detection Technologies

• Liquid biopsy innovations:
  • EpiC-seq: Detects circulating nucleosome PTMs at ultralow frequencies (LoD: 0.01%)
  • Nanopore direct sequencing: Enables real-time histone modification analysis (Oxford Nanopore prototype)
• Spatial resolution advances: Cut&Tag spatial profiling: Maps PTM heterogeneity within tumor microenvironments

2. AI Integration Strategies

• Multimodal deep learning:
  • Input integration: PTM + genomic + transcriptomic data → Treatment response prediction (accuracy >85%)
  • Case demonstration: DeepEpi model combining H3K27me3/H3K4me3 predicts glioma survival (c-index = 0.91)

3. Intervention Biomarker Applications

• Therapy monitoring: H3K27ac as pharmacodynamic biomarker for HDAC inhibitor efficacy (surrogate for tumor volume)
• Epigenetic vaccine development: Personalized neoantigen vaccines designed using patient-specific H3K9me3 depletion sites

4. Clinical Translation Solutions

• Bottleneck mitigation strategies:

Conclusion: Coexisting Opportunities and Challenges

• Core biomarker advantages:
  • Early diagnosis (superior to conventional markers)
  • Dynamic therapy response monitoring
  • Precision guidance for epigenetic drug regimens
• Critical limitations:
  • Insufficient technical sensitivity (particularly in liquid biopsy)
  • Undeciphered biological complexity
  • Limited clinical validation (most cohorts n<100)
• Future directions:
  • Large-scale validation: 10,000+ tumor PTM atlas (multi-center cohorts)
  • Point-of-care devices: Bedside H3K9ac quantification tools
  • Stratified trials: Prospective H3K27me3-guided therapy studies (e.g., NCT05189210)

Understanding histone ptms in neurobiology can be consulted "Histone PTMs in Neurobiology: From Memory to Neurodegeneration".

References

1. Hou JY, Li N, Wang J, Gao LJ, Chang JS, Cao JM. "Histone crotonylation of peripheral blood mononuclear cells is a potential biomarker for diagnosis of colorectal cancer." Epigenetics Chromatin. 2023 Sep 26;16(1):35. doi: 10.1186/s13072-023-00509-3
2. Zhu D, Zhang Y, Wang S. "Histone citrullination: a new target for tumors." Mol Cancer. 2021 Jun 11;20(1):90. doi: 10.1186/s12943-021-01373-z
3. An S, Camarillo JM, Huang TY, Li D, Morris JA, Zoltek MA, Qi J, Behbahani M, Kambhampati M, Kelleher NL, Nazarian J, Thomas PM, Saratsis AM. "Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma." J Exp Clin Cancer Res. 2020 Nov 25;39(1):261. doi: 10.1186/s13046-020-01773-x
4. Fontes-Sousa M, Lobo J, Lobo S, Salta S, Amorim M, Lopes P, Antunes L, de Sousa SP, Henrique R, Jerónimo C. "Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence." Mol Med. 2020 Feb 12;26(1):22. doi: 10.1186/s10020-020-0147-5
5. Fan T, Xiao C, Deng Z, Li S, Tian H, Zheng Y, Zheng B, Li C, He J. "Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9." Respir Res. 2025 Jan 15;26(1):17. doi: 10.1186/s12931-024-03093-6
6. Qi Y, Li B, Wen Y, Yang X, Chen B, He Z, Zhao Z, Magdalou J, Wang H, Chen L. "H3K9ac of TGFβRI in human umbilical cord: a potential biomarker for evaluating cartilage differentiation and susceptibility to osteoarthritis via a two-step strategy." Stem Cell Res Ther. 2021 Mar 4;12(1):163. doi: 10.1186/s13287-021-02234-8
7. van Dijk AD, Hoff FW, Qiu YH, Chandra J, Jabbour E, de Bont ESJM, Horton TM, Kornblau SM. "Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia." Clin Epigenetics. 2021 Jan 28;13(1):21. doi: 10.1186/s13148-021-01011-x